These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24528215)

  • 1. Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users.
    Verhoef TI; Redekop WK; Bouvy ML; Dorenbos B; Karwar Z; van Schie RM; de Boer A; Maitland-van der Zee AH;
    Br J Clin Pharmacol; 2014 Aug; 78(2):422-9. PubMed ID: 24528215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
    Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
    Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
    J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
    Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):454-464. PubMed ID: 27992949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose.
    van Schie RM; Verhoef TI; Boejharat SB; Schalekamp T; Wessels JA; le Cessie S; Rosendaal FR; van der Meer FJ; de Boer A; Maitland-van der Zee AH
    Drug Metabol Drug Interact; 2012; 27(4):229-34. PubMed ID: 23096528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
    Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
    N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.
    Verhoef TI; Redekop WK; de Boer A; Maitland-van der Zee AH;
    Pharmacogenomics; 2015 Jan; 16(2):101-14. PubMed ID: 25616097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenprocoumon and acenocoumarol treatment in paediatric patients.
    Spoor N; Smiers FJ; van der Meer FJ; Hutten BA; van Ommen CH
    Thromb Haemost; 2012 Dec; 108(6):1238-41. PubMed ID: 23014894
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
    Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
    Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extent and quality of anti-coagulation treatment with coumarin derivatives by the Dutch Thrombosis Services].
    van Geest-Daalderop JH; Sturk A; Levi M; Adriaansen HJ
    Ned Tijdschr Geneeskd; 2004 Apr; 148(15):730-5. PubMed ID: 15119208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
    van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
    PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin use decreases coagulation in users of vitamin K antagonists.
    van Rein N; Biedermann JS; Bonafacio SM; Kruip MJ; van der Meer FJ; Lijfering WM
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1441-1447. PubMed ID: 27709253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
    Becker ML; Franken WP; Karapinar F; Verzijl-Zeegers R; Schalekamp T; van der Hoeven RT
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1461-5. PubMed ID: 26400679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of OTC drug noscapine and acenocoumarol and phenprocoumon.
    Lokhorst B; Rolfes L; Jessurun NT
    Br J Clin Pharmacol; 2019 May; 85(5):1041-1043. PubMed ID: 30809820
    [No Abstract]   [Full Text] [Related]  

  • 17. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
    Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
    van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
    Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Wilms EB; Veldkamp RF; van Meegen E; Touw DJ
    Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2095-8. PubMed ID: 17036862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
    Fihn SD; Gadisseur AA; Pasterkamp E; van der Meer FJ; Breukink-Engbers WG; Geven-Boere LM; van Meegen E; de Vries-Goldschmeding H; Antheunissen-Anneveld I; van't Hoff AR; Harderman D; Smink M; Rosendaal FR
    Thromb Haemost; 2003 Aug; 90(2):260-6. PubMed ID: 12888873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.